AMR Action Fund
The AMR Action Fund is the world's largest venture capital fund dedicated exclusively to antimicrobial therapeutics, investing in clinical-stage biotechs developing treatments for WHO and CDC priority pathogens with over US$1 billion pledged from leading pharmaceutical companies and global health institutions.
- Company typePrivate
- Founded2020
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What AMR Action Fund does
The AMR Action Fund is the world's largest venture capital fund dedicated exclusively to antimicrobial therapeutics, structured as a public-private partnership and operated by AMR Action Fund GP, S.à r.l. (Luxembourg). Launched in July 2020 by more than 20 leading biopharmaceutical companies under the auspices of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), in collaboration with the World Health Organization, the European Investment Bank, and Wellcome Trust, the Fund has over US$1 billion pledged with a stated objective of bringing 2 to 4 new antimicrobials to patients by 2030. It is headquartered in Boston, MA with a European office in Basel, Switzerland.
The Fund invests in small and mid-size, clinical-stage biotechnology companies developing treatments for WHO and CDC priority pathogens, spanning traditional small-molecule antibiotics, bacteriophage therapies, peptide therapeutics, and antibody-based immunotherapies. Its portfolio includes BioVersys, BiomX, Venatorx Pharmaceuticals, Vedanta Biosciences, Pattern Bioscience, Antabio, Utility Therapeutics, Elion Therapeutics, TenNor Therapeutics, F2G, Peptilogics, Centauri Therapeutics, and Adaptive Phage Therapeutics. Investments are typically executed through direct equity participation — leading or co-leading Series B/C and Series A extension rounds — and syndicated with global financial partners. An independent 9-member Scientific Advisory Board chaired by Dr. John H. Rex provides scientific evaluation of prospective investments.
The Fund's revenue model is venture-fund economics applied to a public-private partnership structure: management fees on committed/deployed capital, with the long-term economic thesis dependent on portfolio exits via M&A, IPOs, or product launches. In parallel with capital deployment, the Fund actively advocates for antimicrobial market reform — including pull-incentive mechanisms such as the PASTEUR Act and subscription-style reimbursement — and pursues policy partnerships (e.g., BEAM Alliance, Danish AMR Alliance, Novo Nordisk Foundation, UICC/BD Cancer and AMR Consortium) to create a sustainable commercial ecosystem. Notable portfolio milestones include the April 2024 FDA approval of pivmecillinam (PIVYA) via Utility Therapeutics and Alembic Pharmaceuticals' subsequent acquisition of Utility in July 2025.
AMR Action Fund firmographics
Firmographics- Name
- AMR Action Fund
- Legal name
- AMR Action Fund GP, S.à r.l.
- Website
- https://amractionfund.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- The AMR Action Fund is the world's largest venture capital fund dedicated exclusively to antimicrobial therapeutics, investing in clinical-stage biotechs developing treatments for WHO and CDC priority pathogens with over US$1 billion pledged from leading pharmaceutical companies and global health institutions.
- Ownership category
- akta.pro rank
AMR Action Fund industry classification
Industry- Product category
- Venture Capital / Life Sciences Investment
- NAICS
- Portfolio Management and Investment Advice (523940), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Healthcare Access & Life Sciences Impact Funds (FSANAJAI)
- akta.pro secondary industries
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG), Early-Stage Venture Capital (Series A/B) (FSANAAAB)
Keywords
Where AMR Action Fund is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
AMR Action Fund business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Investment Returns from Portfolio Companies: The AMR Action Fund is a venture capital fund that generates returns through equity investments in clinical-stage biotech companies developing antimicrobial therapeutics. Returns come from successful exits via M&A, IPOs, or product launches of portfolio companies.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels7 records
AMR Action Fund product offering
Product offeringCore offering
The AMR Action Fund is the world's largest venture capital fund dedicated exclusively to antimicrobial therapeutics. It deploys equity capital (over $1 billion pledged) into clinical-stage biotech companies developing treatments for WHO and CDC priority pathogens, spanning traditional small-molecule compounds, bacteriophages, peptide therapeutics, and antibody-based therapies. The Fund also advocates for policy reforms such as subscription and pull-incentive models to create a sustainable market for new antibiotics.
Product overview
The AMR Action Fund is the world's largest venture capital fund dedicated exclusively to antimicrobial therapeutics, deploying approximately $1 billion to invest in clinical-stage biotech companies developing urgently needed treatments for WHO and CDC priority bacterial and fungal pathogens. The Fund operates as a single investment platform focused on enabling 2-4 new antimicrobials by 2030, investing in companies pursuing both traditional small-molecule compounds and innovative modalities including bacteriophage therapy, peptide therapeutics, and antibody-based immunotherapies. The portfolio spans 12+ companies addressing critical threats including carbapenem-resistant Acinetobacter baumannii (CRAB), C. difficile infections, prosthetic joint infections, and invasive fungal infections.
Differentiator
Problem solved
Functional benefit
Products and services
- AMR Action Fund Investment Portfolio Equity investments in small and mid-size clinical-stage biotech companies developing antimicrobial therapeutics for WHO and CDC priority pathogens, including both traditional small-molecule compounds and innovative modalities such as bacteriophages, peptide therapeutics, and antibody treatments.
Quantifiable outcome
- Aims to bring 2-4 new antimicrobials to patients by 2030
- +2 more outcomes
Companies that use AMR Action Fund
Customer profileNamed customers13 records
Segments3 records
Ideal customer profiles2 records
AMR Action Fund technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AMR Action Fund partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered strategic and core.
- Cancer and AMR Consortium (with Union for International Cancer Control and BD)strategicThe AMR Action Fund helped establish the Cancer and AMR Consortium in collaboration with the Union for International Cancer Control (UICC) and BD to address the threat AMR poses to cancer patients.
- Danish AMR AlliancestrategicCo-organized European Parliament event on antibiotics and health security together with BEAM Alliance, AMR Action Fund, and Novo Nordisk Foundation.
- BEAM AlliancestrategicCo-organized European Parliament event on antibiotics and health security together with Danish AMR Alliance, AMR Action Fund, and Novo Nordisk Foundation.
- World Health OrganizationcoreWHO collaborated with IFPMA and pharmaceutical companies to develop the concept for the AMR Action Fund. The Fund invests in treatments targeting WHO priority pathogens and aligns its scientific charter with WHO's AMR priorities.
- International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)coreIFPMA originated the concept for the AMR Action Fund in collaboration with member companies, WHO, European Investment Bank, and Wellcome Trust. IFPMA represents the R&D pharmaceutical industry internationally.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
AMR Action Fund competitors and assessment
Company assessmentDirect peers
- CARB-X: Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator is a global non-profit partnership focused on accelerating antibacterial products to address drug-resistant infections. Directly comparable as another public-private AMR-focused funding entity with $480M+ committed, targeting the same portfolio-stage biotech companies and offering complementary non-dilutive and dilutive capital.
- Global Antibiotic R&D Partnership (GARDP): Swiss-based non-profit developing new antibiotic treatments and ensuring sustainable access. Directly comparable as a mission-driven public-private partnership developing and funding new antibiotics for priority pathogens; shares the AMR Action Fund's advocacy stance on access and stewardship principles.
- Boehringer Ingelheim Venture Fund: Corporate venture arm of Boehringer Ingelheim (also an AMR Action Fund LP) with portfolio including Centauri Therapeutics. Comparable as a strategic corporate VC investing in early-stage biotech with therapeutic focus including infectious diseases, and overlaps directly on portfolio companies.
- Novo Ventures: Venture arm of Novo Holdings (associated with Novo Nordisk Foundation, an AMR Action Fund LP). Comparable as a large life sciences VC platform with significant biotech portfolio and global mandate; shares pharma/sovereign LP architecture and investment themes in biotech innovation.
- Novartis Venture Fund: Corporate VC arm of Novartis (also an AMR Action Fund LP), led previously by AMR Action Fund CEO Henry Skinner. Comparable as a strategic life sciences VC investing in early-stage therapeutics and providing syndication to AMR Action Fund portfolio companies.
- Wellcome Trust: Global charitable foundation focused on health research and a major AMR Action Fund LP ($66.8M). Comparable as a major AMR-focused philanthropic investor with their own direct investment programs in infectious disease therapeutics and a global advocacy mandate for pull incentives.
- SR One (GSK): Life sciences venture firm affiliated with GlaxoSmithKline (also an AMR Action Fund LP). Comparable as a strategic biotech VC investing in early-stage therapeutics including infectious disease, often co-investing in clinical-stage assets alongside other pharma-affiliated VCs.
Others
- BARDA (Biomedical Advanced Research and Development Authority): US HHS division providing funding for advanced development of medical countermeasures, including antibiotics targeting AMR threats. Comparable as a complementary non-dilutive funding source frequently used by AMR Action Fund portfolio companies to bridge development gaps.
- European Investment Bank: EU lending institution and AMR Action Fund LP ($24.1M, 2021). Comparable as a public financier of healthcare/biotech innovation including AMR therapeutics under Horizon Europe programs, often co-funding alongside the AMR Action Fund in European portfolio companies.
Emerging players
- Versant Ventures: Healthcare-focused VC with deep biotech franchise and history of launching clinical-stage companies including infectious disease plays. Comparable as a competing investor in clinical-stage biotech including potential AMR-relevant assets, frequently co-investing with corporate VC LPs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
AMR Action Fund social profiles
Digital presenceAMR Action Fund financial estimates
Financial estimateRevenue estimate
Valuation estimate
AMR Action Fund leadership team
Management profileNumber of profiles
Profiles13 records
AMR Action Fund funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AMR Action Fund M&A and investment
M&A and investmentM&A
Investments15 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AMR Action Fund
What does AMR Action Fund do?
The AMR Action Fund is the world's largest venture capital fund dedicated exclusively to antimicrobial therapeutics. It deploys equity capital (over $1 billion pledged) into clinical-stage biotech companies developing treatments for WHO and CDC priority pathogens, spanning traditional small-molecule compounds, bacteriophages, peptide therapeutics, and antibody-based therapies. The Fund also advocates for policy reforms such as subscription and pull-incentive models to create a sustainable market for new antibiotics.
Is AMR Action Fund a public or private company?
AMR Action Fund is a private company. It is classified as venture growth investor backed and is currently operating.
When was AMR Action Fund founded?
AMR Action Fund was founded in 2020. It employs 11 to 50 people.
Where is AMR Action Fund based?
AMR Action Fund is headquartered in Boston, United States, in the North America region.
How does AMR Action Fund make money?
One revenue line is on record: investment Returns from Portfolio Companies.
Who are AMR Action Fund's main competitors?
Direct peers on record are CARB-X, Global Antibiotic R&D Partnership (GARDP), Boehringer Ingelheim Venture Fund, Novo Ventures, Novartis Venture Fund, Wellcome Trust and SR One (GSK). Others are BARDA (Biomedical Advanced Research and Development Authority) and European Investment Bank. Versant Ventures is listed as an emerging player.
Does AMR Action Fund have an API?
No public API is recorded for AMR Action Fund.
What industry is AMR Action Fund in?
AMR Action Fund's product category is Venture Capital / Life Sciences Investment. Its primary akta.pro industry code is FSANAJAI, Healthcare Access & Life Sciences Impact Funds, with a secondary code of HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 523940 and its SIC code is 6282.